The Cystic Fibrosis Foundation (“CF Foundation” or “we”) is committed to protecting your privacy. This Privacy Statement explains what type of information we may collect and how we may collect, retain, process, share, and transfer that information from website visitors and other individuals with whom we interact, whether online or offline, why we collect it, and with whom we may share it. It also describes how we protect your personal information and how you can contact us with any questions or to exercise the rights you may have to control our use of your information.
Site Search
The Cystic Fibrosis Foundation (CFF) is committed to protecting your privacy. This Privacy Statement explains the types of personal information we may collect from website visitors and other individuals with whom we interact, whether online or offline, why we collect it, and with whom we may share it. It also describes how we protect your personal information and how you can contact us with any questions.
The "65 Roses" story dates back to 1965 when an observant 4-year-old, hearing the name of his disease for the first time, pronounced cystic fibrosis as "65 Roses." Today, "65 Roses" is a term often used by young children with cystic fibrosis to pronounce the name of their disease.
The Cystic Fibrosis Foundation is a people-centered organization that offers a unifying mission that guides our work, generous benefits, and rewarding career opportunities across multiple disciplines.
This purchase order agreement is designed for vendors that wish to agree to our standard terms and conditions and receive approved payment more quickly.
The mission of the Cystic Fibrosis Foundation is to cure cystic fibrosis and to provide all people with CF the opportunity to lead long, fulfilling lives by funding research and drug development, partnering with the CF community, and advancing high-quality, specialized care.
Members of the council lend their voices to convey the hopes, needs, and aspirations of the CF adult community.
Scientists around the world agree that global innovation is needed to address the shortage of effective antibiotics. Our Infection Research Initiative supports much-needed research and development, but new policies are needed to promote a sustainable, robust antibiotics pipeline and a marketplace that rewards innovation.
Learn more about President and Chief Executive Officer Michael Boyle, MD.
View our leaders, including our Board Chair, corporate officers, and senior staff.